welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
A Study of TAS-205 for Duchenne Muscular Dystrophy
study id #: NCT02246478
condition: Duchenne Muscular Dystrophy
status: completed
purpose:The objective of this study is to evaluate the safety and pharmacokinetic of TAS-205 in patients with Duchenne Muscular Dystrophy.
intervention: TAS-205, Placebo
mechanism of action: HPGDS inhibitor to modulate effects of inflammation
results: https://clinicaltrials.gov/ct2/show/results/NCT02246478
last updated: November 22, 2018
rareRelated
-
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
-
PDE Inhibitors in DMD Study (Acute Dosing Study)PDE5A inhibition, which boosts NO-cGMP s...
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMDThis is a controlled, open-label, single...
-
Safety and Efficacy of P-188 NF in DMD PatientsThis is an open-label study to evaluate ...
-
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
-
Duchenne Muscular Dystrophy Clinical TrialThe primary objective of this investigat...
-
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
-
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
-
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients With Duchenne Muscular Dystrophy Tr...Capricor Therapeutics, a clinical-stage ...
-
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
-
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...